EGFR Inhibition in NSCLC: New Findings…. And Opened Questions?

Critical Reviews in Oncology/Hematology - Netherlands
doi 10.1016/j.critrevonc.2017.02.009
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Elsevier BV

Related search

Urea Cycle Sustains Cellular Energetics Upon EGFR Inhibition in EGFR Mutant NSCLC

Molecular Cancer Research
Cancer ResearchOncologyMolecular Biology
2019English

REVIEW: Noted: Questions of Great Intricacy Opened Up to Non-Arabic Audience

Pacific Journalism Review
Communication
2017English

Introduction: One Hundred Year Old Questions, Novel Paradigms and New Findings on Emotion

PSICOLOGIA
Psychology
2014English

Comparison of EGFR-TKI and Chemotherapy in the First-Line Treatment of Advanced EGFR Mutation-Positive NSCLC

Neoplasma
Cancer Research
2013English

Bisphosphonates Enhance Antitumor Effect of EGFR-TKIs in Patients With Advanced EGFR Mutant NSCLC and Bone Metastases

Scientific Reports
Multidisciplinary
2017English

Systemic Treatment in EGFR-ALK NSCLC Patients: Second Line Therapy and Beyond

Expert Review of Anticancer Therapy
OncologyPharmacology
2014English

Switching From First or Second Generation EGFR-TKI to Osimertinib in EGFR Mutation-Positive NSCLC

Lung Cancer Management
2020English

Combination of EGFR-TKIs With Chemotherapy Versus Chemotherapy or EGFR-TKIs Alone in Advanced NSCLC Patients With EGFR Mutation

Biologics: Targets and Therapy
OncologyImmunologyGastroenterologyPharmacologyRheumatologyAllergy
2018English

P1.04-09 Immunomodulatory Effects of Afatinib and Pembrolizumab in EGFR-Mutant NSCLC With Progression on Prior EGFR-TKI

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2018English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy